Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (6): 540-545.DOI: 10.3969/j.issn.1673-8640.2020.06.006
Previous Articles Next Articles
WANG Bin1, YUAN Xu1, HAN Feng2, TANG Ning1()
Received:
2020-03-13
Online:
2020-06-30
Published:
2020-07-01
CLC Number:
WANG Bin, YUAN Xu, HAN Feng, TANG Ning. Relevant factors on short-term critical events in patients with corona virus disease 2019[J]. Laboratory Medicine, 2020, 35(6): 540-545.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.06.006
组别 | 例数 | 性别/ 例(%) | 年龄/ 岁 | 冠心病史/ 例(%) | 高血压史/ 例(%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性 | 女性 | 无 | 有 | 无 | 有 | ||||||||||
非危重组 | 49 | 21(42.90) | 28(57.10) | 63(46~70) | 44(89.80) | 5(10.20) | 33(67.30) | 16(32.70) | |||||||
危重组 | 24 | 16(66.70) | 8(33.30) | 72(59~79) | 21(87.50) | 3(12.50) | 13(54.20) | 11(45.80) | |||||||
统计值 | 3.654 | -2.734 | 0.000 | 1.201 | |||||||||||
P值 | 0.056 | 0.006 | 1.000 | 0.273 | |||||||||||
组别 | 糖尿病史/ 例(%) | 结核病史/ 例(%) | 死亡/ 例(%) | ||||||||||||
无 | 有 | 无 | 有 | 无 | 有 | ||||||||||
非危重组 | 45(91.80) | 4(8.20) | 48(98.00) | 1(2.00) | 49(100.00) | 0(0.00) | |||||||||
危重组 | 16(66.70) | 8(33.30) | 24(100.00) | 0(0.00) | 15(62.50) | 9(37.50) | |||||||||
统计值 | 5.711 | ||||||||||||||
P值 | 0.017 | 1.000 | <0.001 |
组别 | 例数 | 性别/ 例(%) | 年龄/ 岁 | 冠心病史/ 例(%) | 高血压史/ 例(%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男性 | 女性 | 无 | 有 | 无 | 有 | ||||||||||
非危重组 | 49 | 21(42.90) | 28(57.10) | 63(46~70) | 44(89.80) | 5(10.20) | 33(67.30) | 16(32.70) | |||||||
危重组 | 24 | 16(66.70) | 8(33.30) | 72(59~79) | 21(87.50) | 3(12.50) | 13(54.20) | 11(45.80) | |||||||
统计值 | 3.654 | -2.734 | 0.000 | 1.201 | |||||||||||
P值 | 0.056 | 0.006 | 1.000 | 0.273 | |||||||||||
组别 | 糖尿病史/ 例(%) | 结核病史/ 例(%) | 死亡/ 例(%) | ||||||||||||
无 | 有 | 无 | 有 | 无 | 有 | ||||||||||
非危重组 | 45(91.80) | 4(8.20) | 48(98.00) | 1(2.00) | 49(100.00) | 0(0.00) | |||||||||
危重组 | 16(66.70) | 8(33.30) | 24(100.00) | 0(0.00) | 15(62.50) | 9(37.50) | |||||||||
统计值 | 5.711 | ||||||||||||||
P值 | 0.017 | 1.000 | <0.001 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/ (ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 55 | 13.9(13.4~14.5) | 40.3(36.6~40.3) | 5.4 (4.5~5.8) | 16.6(16.3~17.3) | 1.0(0.5~1.8) | 88 (87~88) | 5.4(3.9~6.7) |
危重组 | 18 | 15.4(13.8~18.5) | 37.7(34.4~41.6) | 4.2 (2.9~6.4) | 17.8(16.3~20.3) | 4.4(1.4~4.6) | 84 (79~94) | 10.3(4.4~17.5) |
P值 | 0.013 | 0.143 | 0.189 | 0.026 | 0.002 | 0.649 | 0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/(×109/L) | CRP/(mg/L) | ALT/(U/L) | AST/(U/L) | BUN/(mmol/L) | Cr/(mmol/L) | |
非危重组 | 1.0 (0.7~1.3) | 209(167~267) | 34.1(12.0~78.7) | 26 (14~37) | 25 (18~32) | 4.3(3.5~5.4) | 72 (58~87) | |
危重组 | 0.7 (0.6~1.0) | 102(53~165) | 103.3(50.4~211.5) | 29 (18~60) | 41(27~113) | 10.4(5.6~27.8) | 99(68~177) | |
P值 | 0.076 | 0.001 | <0.001 | 0.304 | 0.008 | 0.007 | 0.043 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/ (ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 55 | 13.9(13.4~14.5) | 40.3(36.6~40.3) | 5.4 (4.5~5.8) | 16.6(16.3~17.3) | 1.0(0.5~1.8) | 88 (87~88) | 5.4(3.9~6.7) |
危重组 | 18 | 15.4(13.8~18.5) | 37.7(34.4~41.6) | 4.2 (2.9~6.4) | 17.8(16.3~20.3) | 4.4(1.4~4.6) | 84 (79~94) | 10.3(4.4~17.5) |
P值 | 0.013 | 0.143 | 0.189 | 0.026 | 0.002 | 0.649 | 0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/(×109/L) | CRP/(mg/L) | ALT/(U/L) | AST/(U/L) | BUN/(mmol/L) | Cr/(mmol/L) | |
非危重组 | 1.0 (0.7~1.3) | 209(167~267) | 34.1(12.0~78.7) | 26 (14~37) | 25 (18~32) | 4.3(3.5~5.4) | 72 (58~87) | |
危重组 | 0.7 (0.6~1.0) | 102(53~165) | 103.3(50.4~211.5) | 29 (18~60) | 41(27~113) | 10.4(5.6~27.8) | 99(68~177) | |
P值 | 0.076 | 0.001 | <0.001 | 0.304 | 0.008 | 0.007 | 0.043 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/(ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 49 | 13.8(13.4~14.3) | 40.3(36.9~41.3) | 5.8 (4.3~5.8) | 16.6 (16.5~16.7) | 1.7(0.7~1.7) | 88 (87~88) | 6.7(4.6~8.5) |
危重组 | 22 | 15.7(14.2~18.4) | 41.3(36.7~45.4) | 3.9 (1.6~5.3) | 18.8(16.7~21.9) | 4.6(4.6~7.9) | 84 (83~88) | 14.5(9.4~17.9) |
P值 | <0.001 | 0.277 | 0.002 | 0.006 | <0.001 | 0.013 | <0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/ (×109/L) | CRP/(mg/L) | ALT/(U/L) | AST/(U/L) | BUN/(mmol/L) | Cr/(mmol/L) | |
非危重组 | 1.2 (0.9~1.7) | 259(190~307) | 34.1(13.9~34.1) | 22 (13~37) | 25 (14~32) | 4.8(3.6~5.5) | 71 (53~76) | |
危重组 | 0.3 (0.2~0.6) | 134(52~258) | 70.9(33.4~109.9) | 23 (14~49) | 39 (22~47) | 9.3(4.4~16.6) | 67.5(60~142) | |
P值 | <0.001 | 0.004 | 0.002 | 0.802 | 0.043 | 0.015 | 0.525 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/(ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 49 | 13.8(13.4~14.3) | 40.3(36.9~41.3) | 5.8 (4.3~5.8) | 16.6 (16.5~16.7) | 1.7(0.7~1.7) | 88 (87~88) | 6.7(4.6~8.5) |
危重组 | 22 | 15.7(14.2~18.4) | 41.3(36.7~45.4) | 3.9 (1.6~5.3) | 18.8(16.7~21.9) | 4.6(4.6~7.9) | 84 (83~88) | 14.5(9.4~17.9) |
P值 | <0.001 | 0.277 | 0.002 | 0.006 | <0.001 | 0.013 | <0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/ (×109/L) | CRP/(mg/L) | ALT/(U/L) | AST/(U/L) | BUN/(mmol/L) | Cr/(mmol/L) | |
非危重组 | 1.2 (0.9~1.7) | 259(190~307) | 34.1(13.9~34.1) | 22 (13~37) | 25 (14~32) | 4.8(3.6~5.5) | 71 (53~76) | |
危重组 | 0.3 (0.2~0.6) | 134(52~258) | 70.9(33.4~109.9) | 23 (14~49) | 39 (22~47) | 9.3(4.4~16.6) | 67.5(60~142) | |
P值 | <0.001 | 0.004 | 0.002 | 0.802 | 0.043 | 0.015 | 0.525 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/(ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 49 | 13.8(13.4~13.8) | 40.3(36.0~40.3) | 5.8 (3.7~5.8) | 16.6(16.4~16.8) | 1.7 (1~1.8) | 89 (88~89) | 6.1(5.3~8.2) |
危重组 | 21 | 16.4(15.3~17.8) | 42.1(39.4~52.7) | 4.0 (1.9~5.0) | 18.1(16~20.1) | 4.6(2.8~4.6) | 84 (72~85) | 13.0(9.6~16.9) |
P值 | <0.001 | 0.021 | 0.018 | 0.051 | <0.001 | <0.001 | <0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/ (×109/L) | CRP/ (mg/L) | ALT/ (U/L) | AST/ (U/L) | BUN/(mmol/L) | Cr/ (mmol/L) | |
非危重组 | 1.4 (1.0~1.8) | 256(197~306) | 12.5(2.0~34.1) | 30 (18~50) | 23 (19~32) | 4.8(3.3~5.9) | 71 (52~83) | |
危重组 | 0.4 (0.2~0.9) | 225(31~277) | 67.9(53.8~101.3) | 32 (15~36) | 38 (29~43) | 7.5(4.1~22.9) | 72(58~144) | |
P值 | <0.001 | 0.200 | <0.001 | 0.787 | 0.039 | 0.018 | 0.328 |
组别 | 例数 | PT/s | APTT/s | Fg/(g/L) | TT/s | DD/(ug/mL) | AT/% | WBC计数/ (×109/L) |
---|---|---|---|---|---|---|---|---|
非危重组 | 49 | 13.8(13.4~13.8) | 40.3(36.0~40.3) | 5.8 (3.7~5.8) | 16.6(16.4~16.8) | 1.7 (1~1.8) | 89 (88~89) | 6.1(5.3~8.2) |
危重组 | 21 | 16.4(15.3~17.8) | 42.1(39.4~52.7) | 4.0 (1.9~5.0) | 18.1(16~20.1) | 4.6(2.8~4.6) | 84 (72~85) | 13.0(9.6~16.9) |
P值 | <0.001 | 0.021 | 0.018 | 0.051 | <0.001 | <0.001 | <0.001 | |
组别 | Ly计数/(×109/L) | PLT计数/ (×109/L) | CRP/ (mg/L) | ALT/ (U/L) | AST/ (U/L) | BUN/(mmol/L) | Cr/ (mmol/L) | |
非危重组 | 1.4 (1.0~1.8) | 256(197~306) | 12.5(2.0~34.1) | 30 (18~50) | 23 (19~32) | 4.8(3.3~5.9) | 71 (52~83) | |
危重组 | 0.4 (0.2~0.9) | 225(31~277) | 67.9(53.8~101.3) | 32 (15~36) | 38 (29~43) | 7.5(4.1~22.9) | 72(58~144) | |
P值 | <0.001 | 0.200 | <0.001 | 0.787 | 0.039 | 0.018 | 0.328 |
项目 | B值 | 标准误 | Wald值 | 自由度 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|---|
下限 | 上限 | |||||||
年龄 | 0.043 | 0.038 | 1.304 | 1 | 0.253 | 1.044 | 0.970 | 1.124 |
无糖尿病史 | -1.046 | 0.994 | 1.109 | 1 | 0.292 | 0.351 | 0.050 | 2.463 |
APTT | 0.032 | 0.079 | 0.166 | 1 | 0.683 | 1.033 | 0.884 | 1.207 |
AT | -0.038 | 0.053 | 0.509 | 1 | 0.476 | 0.963 | 0.868 | 1.068 |
DD | 0.452 | 0.213 | 4.497 | 1 | 0.034 | 1.571 | 1.035 | 2.386 |
Fg | -0.561 | 0.361 | 2.418 | 1 | 0.120 | 0.571 | 0.281 | 1.157 |
PT | 0.275 | 0.270 | 1.036 | 1 | 0.309 | 1.316 | 0.775 | 2.234 |
TT | 0.547 | 0.303 | 3.260 | 1 | 0.071 | 1.729 | 0.954 | 3.132 |
CRP | 0.022 | 0.012 | 3.090 | 1 | 0.079 | 1.022 | 0.997 | 1.047 |
WBC计数 | 0.040 | 0.117 | 0.115 | 1 | 0.734 | 1.040 | 0.827 | 1.308 |
LY计数 | -0.848 | 1.015 | 0.699 | 1 | 0.403 | 0.428 | 0.059 | 3.130 |
PLT计数 | -0.016 | 0.008 | 4.406 | 1 | 0.036 | 0.984 | 0.969 | 0.999 |
ALT | 0.040 | 0.024 | 2.661 | 1 | 0.103 | 1.041 | 0.992 | 1.092 |
AST | -0.023 | 0.022 | 1.112 | 1 | 0.292 | 0.978 | 0.937 | 1.020 |
Cr | -0.012 | 0.014 | 0.740 | 1 | 0.390 | 0.988 | 0.961 | 1.016 |
BUN | 0.092 | 0.157 | 0.345 | 1 | 0.557 | 1.096 | 0.807 | 1.490 |
常数 | -10.841 | 8.362 | 1.681 | 1 | 0.195 | 0.000 |
项目 | B值 | 标准误 | Wald值 | 自由度 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|---|
下限 | 上限 | |||||||
年龄 | 0.043 | 0.038 | 1.304 | 1 | 0.253 | 1.044 | 0.970 | 1.124 |
无糖尿病史 | -1.046 | 0.994 | 1.109 | 1 | 0.292 | 0.351 | 0.050 | 2.463 |
APTT | 0.032 | 0.079 | 0.166 | 1 | 0.683 | 1.033 | 0.884 | 1.207 |
AT | -0.038 | 0.053 | 0.509 | 1 | 0.476 | 0.963 | 0.868 | 1.068 |
DD | 0.452 | 0.213 | 4.497 | 1 | 0.034 | 1.571 | 1.035 | 2.386 |
Fg | -0.561 | 0.361 | 2.418 | 1 | 0.120 | 0.571 | 0.281 | 1.157 |
PT | 0.275 | 0.270 | 1.036 | 1 | 0.309 | 1.316 | 0.775 | 2.234 |
TT | 0.547 | 0.303 | 3.260 | 1 | 0.071 | 1.729 | 0.954 | 3.132 |
CRP | 0.022 | 0.012 | 3.090 | 1 | 0.079 | 1.022 | 0.997 | 1.047 |
WBC计数 | 0.040 | 0.117 | 0.115 | 1 | 0.734 | 1.040 | 0.827 | 1.308 |
LY计数 | -0.848 | 1.015 | 0.699 | 1 | 0.403 | 0.428 | 0.059 | 3.130 |
PLT计数 | -0.016 | 0.008 | 4.406 | 1 | 0.036 | 0.984 | 0.969 | 0.999 |
ALT | 0.040 | 0.024 | 2.661 | 1 | 0.103 | 1.041 | 0.992 | 1.092 |
AST | -0.023 | 0.022 | 1.112 | 1 | 0.292 | 0.978 | 0.937 | 1.020 |
Cr | -0.012 | 0.014 | 0.740 | 1 | 0.390 | 0.988 | 0.961 | 1.016 |
BUN | 0.092 | 0.157 | 0.345 | 1 | 0.557 | 1.096 | 0.807 | 1.490 |
常数 | -10.841 | 8.362 | 1.681 | 1 | 0.195 | 0.000 |
项目 | AUC(95%CI) | P值 | 临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
DD | 0.820(0.739~0.902) | <0.001 | 3.99 μg/mL | 67.4 | 93.7 |
PLT计数 | 0.764(0.652~0.876) | <0.001 | 163.5×109/L | 60.7 | 85.8 |
DD+ PLT计数 | 0.809(0.703~0.915) | <0.001 | 3.98 | 67.9 | 86.8 |
项目 | AUC(95%CI) | P值 | 临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|---|
DD | 0.820(0.739~0.902) | <0.001 | 3.99 μg/mL | 67.4 | 93.7 |
PLT计数 | 0.764(0.652~0.876) | <0.001 | 163.5×109/L | 60.7 | 85.8 |
DD+ PLT计数 | 0.809(0.703~0.915) | <0.001 | 3.98 | 67.9 | 86.8 |
[1] | 邹海,李慧洋,张有志,等. 新型冠状病毒肺炎重症患者救治的华山模式及其临床意义[J]. 医药导报,2020,39(3):319-322. |
[2] | WANG D,HU B,HU C,et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan,China[J]. JAMA,2020,323(11):1061-1069. |
[3] | HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet,2020,395(10223):497-506. |
[4] | 国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-04)[2020-03-06]. |
[5] | CHEN N,ZHOU M,DONG X,et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China:a descriptive study[J]. Lancet,2020,395(10223):507-513. |
[6] | 方丹,马敬东,官佳轮,等. 武汉地区新型冠状病毒肺炎住院患者消化系统表现的单中心、描述性研究[J/OL]. 中华消化杂志,2020,40. DOI:10.3760/cma.j.issn.0254-1432.2020.0005. |
[7] | MAHALLAWI W H,KHABOUR O F,ZHANG Q,et al.MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile[J]. Cytokine,2018,104:8-13. |
[8] | 陈蕾,刘辉国,刘威,等. 2019新型冠状病毒肺炎29例临床特征分析[J/OL]. 中华结核和呼吸杂志,2020,43. DOI:10.3760/cma.j.issn.1001-0939.2020.0005. |
[9] | LIU W J,ZHAO M,LIU K,et al.T-cell immunity of SARS-CoV:implications for vaccine development against MERS-CoV[J]. Antiviral Res,2017,137:82-92. |
[10] | TANG N,LI D,WANG X,et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost,2020,18(4):844-847. |
[11] | GRALINSKI L E,BANKHEAD A 3rd,JENG S,et al. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury[J]. mBio,2013,4(4):e00271-13. |
[12] | BERRI F,RIMMELZWAAN G F,HANSS M,et al.Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis[J]. PLoS Pathog,2013,9(3):e1003229. |
[13] | LEFRANÇAIS E,ORTIZ-MUÑOZ G,CAUDRILLIER A,et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors[J]. Nature,2017,544(7648):105-109. |
[14] | 刘茜,王荣帅,屈国强,等. 新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]. 法医学杂志,2020,36(1):21-23. |
[15] | YANG M,HON K L,LI K,et al.The effect of SARS coronavirus on blood system:its clinical findings and the pathophysiologic hypothesis[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2003,11(3) :217-221. |
[1] | GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679. |
[2] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[3] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[4] | DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090. |
[5] | YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93. |
[6] | SUN Jiaqi, JIN Weifeng, LI Ping, CHEN Shuzi, LIN Ping, LI Dan, CHEN Qing, WANG Mengxia, ZHU Yuxin. Influence of heat inactivation of blood samples at 56 ℃ for 30 min on psychiatric drug concentration monitoring [J]. Laboratory Medicine, 2022, 37(12): 1174-1177. |
[7] | XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011. |
[8] | HU Bing, LI Gai, ZHANG Huimin. Roles of serum interleukin-6 and D-dimer levels in predicting the risk of cerebral hemorrhage in patients with hypertension [J]. Laboratory Medicine, 2022, 37(1): 63-67. |
[9] | LI Bin, ZHAO Dong, HUANG Rong, GUO Juansun. Role of bone marrow vascular endothelial growth factor levels in patients with diffuse large B-cell lymphoma after treatment [J]. Laboratory Medicine, 2021, 36(5): 480-485. |
[10] | HUANG Fei, ZHANG Chunyan, GUO Wei, PAN Baishen, WANG Beili. Status and problems of SARS-CoV-2 nucleic acid detection [J]. Laboratory Medicine, 2021, 36(5): 554-559. |
[11] | DING Ning, ZHANG Weifeng, CHEN Xiaoyong, ZHAO Kewen. Correlations of mean platelet volume,D-dimer and fibrinogen degradation product levels with cerebral infarction and its pathological degree [J]. Laboratory Medicine, 2021, 36(4): 384-387. |
[12] | HU Senan, TAN Junfeng, PENG Chang, AI Honghong, LI Dan. Role of blood glucose variability in the prognosis of severe corona virus disease 2019 patients [J]. Laboratory Medicine, 2021, 36(4): 400-403. |
[13] | WANG Bin. Correlation between neutrophil-to-lymphocyte ratio and short-term poor prognosis in patients with corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(3): 275-280. |
[14] | ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193. |
[15] | LI Shichao, SHEN Liang, WANG Chunhua, TONG Yanfei, ZHANG Ji. Diagnostic value of SARS-CoV-2 antibody to COVID-19:a meta-analysis [J]. Laboratory Medicine, 2021, 36(1): 39-43. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||